Ocuphire Announces Publications Featuring the Ref-1 Protein, a Transcription Factor Regulator, as a Novel Therapeutic Target for the Treatment of Neovascular Retinal Diseases

Oct 7, 2021

Ocuphire’s Clinical Phase 2b Oral Drug Candidate APX3330 for Retina to be Featured at the OIS [email protected] and ASRS 2021 Annual Meeting

Oct 1, 2021

Ocuphire Pharma Presenting at Three Upcoming Healthcare Conferences This Fall

Sep 27, 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sep 3, 2021

Ocuphire Pharma Presenting at Four Conferences in September

Sep 2, 2021

Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update

Aug 12, 2021

Ocuphire Pharma Presenting at Two Conferences in August

Aug 6, 2021

Ocuphire Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Jul 22, 2021

Ocuphire Selected to Present at Multiple Ophthalmic Conferences in July

Jul 13, 2021

Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2021